Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity

European Respiratory Journal

Volumn 48, Issue 5, 2016, Pages 1517-1519

  Riou, Marianne ^a,b,c,d   Seferian, Andrei ^a,b,c   Savale, Laurent ^a,b,c   Chaumais, Marie Camille ^a,c,e   Guignabert, Christophe ^a,c   Canuet, Matthieu ^d   Magro, Pascal ^f   Rea, Delphine ^g   Sitbon, Olivier ^a,b,c   Jaïs, Xavier ^a,b,c   Humbert, Marc ^a,b,c   Montani, David ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c Universite Paris Sud   (France)

^d HÔPITAL CIVIL   (France)

^e HÔPITAL ANTOINE BÉCLÈRE   (France)

^f UNIVERSITY HOSPITAL OF TOURS   (France)

^g SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; BOSUTINIB; DASATINIB; DIURETIC AGENT; HYDROXYUREA; IMATINIB; NILOTINIB; PREDNISOLONE; TADALAFIL; ANILINE DERIVATIVE; NITRILE; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE;

ADULT; AGED; CASE REPORT; CAUCASIAN; CHRONIC MYELOID LEUKEMIA; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; HEART CATHETERIZATION; HEART DILATATION; HEART FAILURE; HUMAN; LETTER; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MIDDLE AGED; NEW YORK HEART ASSOCIATION CLASS; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; RASH; SIX MINUTE WALK TEST; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VERY ELDERLY; CHEMICALLY INDUCED; LUNG; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANILINE COMPOUNDS; DASATINIB; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUNG; MIDDLE AGED; NITRILES; PLEURAL EFFUSION; PROTEIN KINASE INHIBITORS; QUINOLINES;

EID: 84994276008     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01410-2016     Document Type: Letter

References (15)

1. O'Brien S, Radich JP, Abboud CN, et al. Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw 2014; 12: 1590-1610.
2. Goldblatt M, Huggins JT, Doelken P, et al. Dasatinib-induced pleural effusions: a lymphatic network disorder? Am J Med Sci 2009; 338: 414-417.
3. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128-2137.
4. Galie N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 903-975.
5. Latagliata R, Breccia M, Fava C, et al. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol Oncol 2013; 31: 103-109.
6. Shah NP, Rousselot P, Schiffer C, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol 2016; 91: 869-874.
7. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007; 25: 3908-3914.
8. Gambacorti-Passerini C, Kantarjian HM, Kim D-W, et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol 2015; 90: 755-768.
9. Kantarjian HM, Cortes JE, Kim D-W, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood 2014; 123: 1309-1318.
10. Guignabert C, Phan C, Seferian A, et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest 2016; 126: 3207-3218.
11. Quilot F-M, Georges M, Favrolt N, et al. Pulmonary hypertension associated with ponatinib therapy. Eur Respir J 2016; 47: 676-679.
12. Tu L, Dewachter L, Gore B, et al. Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. Am J Respir Cell Mol Biol 2011; 45: 311-322.
13. Remsing Rix LL, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009; 23: 477-485.
14. Austin ED, Cogan JD, West JD, et al. Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J 2009; 34: 1093-1099.
15. Shepherd J. FDA drug safety podcast for healthcare professionals: Sprycel (dasatinib) and risk of pulmonary arterial hypertension. US Food and Drug Administration. www.fda.gov/Drugs/Drugsafety/DrugSafetyPodcasts/ucm275517.htm Date last accessed: August 1, 2016.